Palliative radiation therapy for gynaecological malignancies.
Patients with advanced, recurrent, or metastatic gynaecological malignancies constitute a heterogenous population with diverse symptomatology. Progressive abdominopelvic disease can result in vaginal or diffuse pelvic bleeding, pain, and visceral or lymphovascular obstruction. Gynaecological cancer can also develop debilitating metastases, in particular to bone, central nervous system, or chest. Radiation therapy is a local-regional treatment modality, that, when applied judiciously, can lead to substantial symptomatic relief and tumour response. Individualized application is necessary, balancing efficacy and patient convenience versus treatment intensity, expected duration of palliation and potential toxicity. Important factors to consider are a patient's performance status, extent and sites of tumour, specific symptoms, and life expectancy. The optimal incorporation of radiotherapy is best achieved in the context of a multidisciplinary approach that addresses all facets of palliative care in patients with incurable gynaecological malignancies, to maximize their quality of life and functional level.
Smith
S C
SC
Department of Radiation Oncology, University of Washington Medical Center, Seattle, WA 98195, USA.
Koh
W J
WJ
D001859:Bone Neoplasms / Q000532:radiotherapy / Q000556:secondary*; D001932:Brain Neoplasms / Q000532:radiotherapy / Q000556:secondary*; D005260:Female; D005833:Genital Neoplasms, Female / Q000532:radiotherapy*; D006801:Humans; D007415:Intestinal Obstruction / Q000532:radiotherapy; D008175:Lung Neoplasms / Q000532:radiotherapy / Q000556:secondary; D008209:Lymphedema / Q000532:radiotherapy; D009364:Neoplasm Recurrence, Local / Q000532:radiotherapy*; D010166:Palliative Care / Q000379:methods*; D017699:Pelvic Pain / Q000532:radiotherapy; D014592:Uterine Hemorrhage / Q000532:radiotherapy